NYSE: KAPA · Life Sciences · 4 alerts · CIK 1962011
Share price
$0.4069Close, Nov 16
Market cap
$1.91M
Shares outstanding
4.69MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kairos Pharma, LTD. filings on SEC EDGAR ↗
Kairos Pharma, Ltd. reported a net loss of $5.03 million for the nine months ended September 30, 2026, compared to a $4.08 million loss in the prior year period. The company remains in the development stage with no revenue, and its cash position decreased to $3.13 million as of September 30, 2026, from $4.49 million at year-end 2025.
Kairos Pharma, Ltd. entered into a third amendment to its existing equity line of credit (ELOC) purchase agreement with Helena Global Investment Opportunities I Ltd. The amendment extends the company's option to use the ELOC for an additional year until December 31, 2028, and follows previous amendments that adjusted the purchase price to 97% of VWAP and shortened the pricing period.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.